Leerink Partnrs Predicts Increased Earnings for AC Immune

AC Immune SA (NASDAQ:ACIU) – Analysts at Leerink Partnrs increased their FY2024 EPS estimates for shares of AC Immune in a report issued on Tuesday, November 5th. Leerink Partnrs analyst M. Goodman now anticipates that the company will post earnings of ($0.60) per share for the year, up from their previous estimate of ($0.81). The consensus estimate for AC Immune’s current full-year earnings is ($0.89) per share. Leerink Partnrs also issued estimates for AC Immune’s Q4 2024 earnings at ($0.20) EPS, FY2025 earnings at ($0.87) EPS and FY2028 earnings at $0.00 EPS.

Other research analysts have also recently issued reports about the company. StockNews.com cut AC Immune from a “buy” rating to a “hold” rating in a research report on Tuesday, October 1st. HC Wainwright reiterated a “buy” rating and set a $16.00 price objective on shares of AC Immune in a research note on Wednesday.

AC Immune Price Performance

Shares of NASDAQ ACIU opened at $3.20 on Friday. The business has a 50-day moving average of $3.27 and a 200-day moving average of $3.46. The stock has a market capitalization of $316.61 million, a price-to-earnings ratio of -6.96 and a beta of 1.28. AC Immune has a fifty-two week low of $2.25 and a fifty-two week high of $5.14.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of ACIU. Silverberg Bernstein Capital Management LLC bought a new position in AC Immune during the second quarter worth about $40,000. Lazard Asset Management LLC acquired a new stake in shares of AC Immune in the first quarter valued at approximately $30,000. BNP Paribas Financial Markets boosted its stake in shares of AC Immune by 315.6% during the 1st quarter. BNP Paribas Financial Markets now owns 11,092 shares of the company’s stock worth $33,000 after acquiring an additional 8,423 shares during the period. Vanguard Capital Wealth Advisors acquired a new position in shares of AC Immune during the 2nd quarter worth approximately $56,000. Finally, China Universal Asset Management Co. Ltd. raised its stake in AC Immune by 63.7% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 19,021 shares of the company’s stock valued at $72,000 after acquiring an additional 7,400 shares during the period. 51.36% of the stock is currently owned by institutional investors and hedge funds.

About AC Immune

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases.